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ABSTRACT
Objective To assess the clinical effect of caudate-
putaminal transplantation of fetal striatal tissue in
Huntington’s disease (HD).
Methods We carried out a follow-up study on 10 HD
transplanted patients and 16 HD not-transplanted
patients. All patients were evaluated with the Unified HD
Rating Scale (UHDRS) whose change in motor, cognitive,
behavioural and functional capacity total scores were
considered as outcome measures. Grafted patients also
received morphological and molecular neuroimaging.
Results Patients were followed-up from disease onset
for a total of 309.3 person-years (minimum 5.3, median
11.2 years, maximum 21.6 years). UHDRS scores have
been available since 2004 (median time of 5.7 years
since onset, minimum zero, maximum 17.2 years).
Median post-transplantation follow-up was 4.3 years,
minimum 2.8, maximum 5.1 years. Adjusted post-
transplantation motor score deterioration rate was
reduced compared to the pretransplantation period, and
to that of not-transplanted patients by 0.9 unit/years
(95% CI 0.2 to 1.6). Cognitive score deterioration was
reduced of 2.7 unit/years (95% CI 0.1 to 5.3). For
grafted patients the 2-year post-transplantation [18F]
fluorodeoxyglucose positron emission tomography (PET)
showed striatal/cortical metabolic increase compared to
the presurgical evaluation; 4-year post-transplantation
PET values were slightly decreased, but remained higher
than preoperatively. [123I]iodobenzamide single photon
emission CT demonstrated an increase in striatal D2-
receptor density during postgrafting follow-up.
Conclusions Grafted patients experienced a milder
clinical course with less pronounced motor/cognitive
decline and associated brain metabolism improvement.
Life-time follow-up may ultimately clarify whether
transplantation permanently modifies the natural course
of the disease, allowing longer sojourn time at less
severe clinical stage, and improvement of overall survival.
INTRODUCTION
Human fetal striatal transplantation is being investi-
gated as possible treatment for Huntington’s
disease (HD),1 with the goal of restoring striatal
function impaired by primary degeneration.2 Pilot
studies have demonstrated the feasibility and safety
of the therapy.3–8 Imaging has shown controversial
data on survival and efficacy of the graft,8–10 and
long-term pathological studies reported its eventual
neuronal degeneration.11 Different graft growth
patterns have been described.5 6 12–14 Even though
alloimmunisation has been reported,13–16 and its
possible role in graft degeneration has been
hypothesised,17 the host/graft immune response is
not well understood. Neoplastic/teratogenic trans-
formation of the graft has never been observed,
while the occurrence of overgrowth has seldom
been reported.18 According to a few long-term
follow-up studies, fetal striatal transplantation pro-
vided a period of clinical improvement in three out
of five patients,9 stability in one out of two,10
while no significant clinical benefit was found in a
group of five patients compared with 12 non-
grafted patients.8 We report the results of a
follow-up study designed to assess disease progres-
sion in 10 consecutive HD transplanted patients
and 16 HD not-transplanted patients, and discuss
how fetal striatal transplantation may affect the
disease course.
PATIENTS AND METHODS
The present clinical investigation has been conducted
according to the Declaration of Helsinki principles.
The study begun in 2004 and it was authorised by
the Italian National Health Institute, National
Transplantation Centre (upon approval by Health
Ministry, Consiglio Superiore di Sanità, Sessione XLV,
Sezione II, 21 July and 22 September 2005, and
acceptance by the National Bioethics Committee). In
particular, items to be fulfilled included: (1) distinct
separation between the research team and the institu-
tion carrying out the pregnancy interruption, (2) lack
of benefits for the transplantation and obstetric teams
and (3) request of donor’s consent after pregnancy
interruption. All patients gave written informed
consent prior to being enrolled in the study. All were
included in the European HD Network
REGISTRY.19
The design is an observational cohort aimed at
describing the disease evolution since onset of
symptoms and any putative changes after trans-
plantation. The series consisted of 26 HD patients
(tables 1 and 2) who were acquainted with the
transplantation programme and adhered to the
protocol. Ten patients asked to undergo transplant-
ation and were grafted between 2006 and 2008—
patients 1, 4, 6, 8 having been partially
described.13 14 All patients were evaluated with the
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Unified HD Rating Scale (UHDRS)20—high functional and cog-
nitive scores denote better performance, low behavioural and
motor scores denote better performance. Moreover, grafted
patients were evaluated according to Core Assessment Program
for Intracerebral Transplantation21 and received MRI, [18F]fluor-
odeoxyglucose ([18F]FDG) positron emission tomography (PET)
and, after a 10-day drug wash-out, [123I]iodobenzamide ([123I]
IBZM) single photon emission CT (SPECT). Details of imaging
techniques are provided in online-only material.
Transplanted patients underwent bilateral, in two sessions 2–6
months apart, stereotactic intrastriatal grafting. Detailed neuro-
transplantation protocols are reported in online-only material. For
each procedure, both ganglionic eminences were dissected from
the floor of the forebrain ventricles of a single legally aborted fetus
(9–12.4 weeks, median 10.5 weeks; viability >80%, mean 87.2
±4.42; with no or negligible haematopoietic contamination mea-
sured as CD45 positive cells, mean 1.4±1.7%). After isolation,
tissue was washed with saline solution and cut into small frag-
ments, gently dissociated and resuspended in 500 μL of saline
solution. 1.5 T MRI (Symphony Siemens, The Netherlands) using
3-dimensional contrast-enhanced T1 MPRAGE sequence was
obtained 1–4 days before each surgery. On the day of intervention,
stereotactic CTwas used to obtain coordinates after coregistration
with the previously acquired MRI. Transplantation was performed
under general anaesthesia, in robotic-assisted conditions
(NeuroMate Schaerer Mayfield, France). Tissue suspension was
transplanted into the caudate head and the precommissural and
postcommissural putamen (3–9 tracks, mean 6.6), within 4–6 h
after abortion. At the level of each track, a total of 50 μL of graft-
ing suspension was injected, using a needle connected to a
Table 1 Demographic and clinical characteristics of 10 Huntington’s disease patients who underwent human fetal striatal transplantation
ID Sex
Onset age in years
(calendar year)
Years of
education
CAG
repeats
Affected
parent
Symptom at
onset DB Drugs (mg/day)
Age in years, at
grafting
1 F 34 (1999) 8 49 Mother Motor 459 PMZ (6); STR (50); DZM (2.5);
TBZ (37.5)
40
2+ M 44 (1995) 8 44 Father Motor 374 PMZ (6); STR (25); DZM (2);
TBZ (12.5); VPA (900)
55
3+ M 44 (1994) 10 48 Unknown Motor 550 STR (200); DZM (5) 56
4 M 21 (1996) 8 60 Mother Motor 514 PMZ (8); TBZ (62.5) 34
5 M 28 (1993) 12 48 Father Motor 350 TBZ (37.5); VPA (300) 42
6 F 33 (1990) 10 42 Father Psychiatric 214 PMZ (6); STR (50); DZM (4);
TBZ (62.5)
52
7+ M 32 (2000) 8 56 Mother Motor 656 TPR (100) 39
8 M 48 (2003) 18 47 Mother Cognitive 552 PMZ (6); STR (25); DZM (2.5);
TBZ (25)
54
9 M 46 (2002) 8 43 Mother Motor 345 STR (150); TBZ (50); AMD
(100)
52
10 M 48 (1999) 8 44 Mother Psychiatric 408 STR (50); DZM (2.5); TBZ
(37.5)
57
+, patient who died; AMD, amantadine; CAG, cytosine-adenine-guanine; DB, disease burden measured as (CAG number–35.5)×age-at-onset23; DZM, diazepam; F, female; ID, patient
identifier; M, male; PMZ: pimozide; STR, sertraline; TBZ, tetrabenazine; TPR, tiapride; VPA, sodium valproate.
Table 2 Demographic and clinical characteristics of 16 not-transplanted Huntington’s disease patients
ID Sex
Onset age in years
(calendar year)
Years of
education
CAG
repeats
Affected
parent
Symptom at
onset DB Drugs (mg/day)
11 M 47 (2003) 14 44 Mother Cognitive 399 PMZ (2); TBZ (25); STR (100)
12 M 38 (2002) 8 47 Mother Psychiatric 437 VPA (1500); TBZ (125); APM (0.5)
13 F 45 (2002) 18 50 Father Motor 652 VPA (150); TBZ (25)
14+ M 30 (1992) 8 49 Father Motor 405 PMZ (4); APM (0.5)
15 M 30 (2000) 5 47 Unknown Motor 345 TBZ (25)
16 M 40 (2000) 8 45 Mother Motor 380 VPA (600); PMZ (4); APM (0.5);
STR (50)
17+ F 39 (1996) 5 50 Father Cognitive 565 PMZ (2)
18 F 37 (1997) 5 47 Unknown Psychiatric 425 None
19 M 55 (2003) 5 47 Mother Psychiatric 632 PMZ (2); TBZ (25)
20 F 50 (2002) 5 43 Mother Psychiatric 375 APM (0.25); STR (50)
21 F 44 (1996) 16 47 Unknown Psychiatric 506 PMZ (0.5); TBZ (37.5); STR (50)
22 F 56 (2000) 8 38 Mother Motor 140 PMZ (6); TPR (200); AMD (200)
23 M 59 (2004) 8 42 Father Motor 383 VPA (1100); APM (0.5); STR (75)
24 F 57 (2004) 5 40 Unknown Motor 256 STR (50)
25 M 40 (2004) 13 43 Father Motor 300 AMD (200)
26+ F 36 (1994) 8 44 Mother Motor 306 VPA (300); STR (25)
+, patient who died; AMD, amantadine; APM, alprazolam; CAG, cytosine-adenine-guanine; DB, disease burden measured as (CAG number–35.5)×age-at-onset23; F, female; ID, patient
identifier; M, male; PMZ: pimozide; STR, sertraline; TBZ, tetrabenazine; TPR, tiapride; VPA, sodium valproate.
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Hamilton syringe. For each procedure (table 3) the estimated
number of grafted cells ranged from 2.85 to 20 millions (median
5.73 millions). Intravenous antibiotic prophylaxis with cefotaxime
(2 g) and teicoplanin (200 mg) daily, started 1 day before surgery
and continued for 6 days; a single intravenous dose of fluconazole
(400 mg) was administered the day of the intervention.
Immunosuppression protocol originally included oral administra-
tion of methylprednisolone (40 mg/daily for 3 days after surgery,
then tapered and discontinued within 2 weeks), azathioprine
(3 mg/kg/daily for 12 months) and cyclosporine A (5 mg/kg/daily
for 12 months) starting from the day before the first procedure.
A serum taken 19 months after her first implant from Patient 1,
and 7 months after immunosuppression was discontinued, eventu-
ally showed positive results for anti-HLA (Human Leukocyte
Antigen) class I and class II antigens.14 Therefore, we modified the
immunosuppression protocol by reintroducing cyclosporine A to
sensitised patients sine die. Cyclosporine A serum levels were
checked weekly for the first 2 months and bimonthly thereafter.
Descriptive statistics and standard statistical procedures—
Student t test, Fisher’s Exact test (α=0.05 two-sided), were used
to summarise group characteristics. Main outcomes were the
deterioration rate in motor, cognitive, behavioural and func-
tional capacity as measured by UHDRS total scores. Repeated
measurements at patient-specific follow-up times were available
(see Results and online-only material table S1A). Therefore, we
described the individual evolution of each outcome by time
since disease onset. Transplantation was considered a time-
varying binary variable, and we evaluated if transplantation was
associated to a change in the deterioration rate for each
outcome. To this purpose, for each outcome separately, we
fitted a series of linear mixed models with subject-specific
random intercepts.22 For simplicity’s sake, we fitted a linear
time trend. The transplantation effect was modelled as
change-in-slope after grafting, specified by an interaction term.
We used baseline measurement of disease burden23 and an inter-
action term between disease burden and time to take into
account any potential regression to the mean effect.24 25 Age,
gender, education, cytosine-adenine-guanine (CAG) repeats
were considered potential confounders. A series of linear mixed
models including confounders and testing for interactions were
fitted; in this phase, we checked for homogeneity of not-
transplanted patients’ time profiles and the pretransplantation
time profiles of the transplanted patients. We also fitted linear
mixed models to grafted case series only. That analysis is
expected to be more sensitive but, being based on fewer sub-
jects, to provide less robust results. Results are expressed as
point and interval estimates at 95% CI. On analysing multiple
outcomes, we applied the Benjamini–Hochberg procedure to
control the false discovery rate at 10%.26 A sensitivity analysis
was conducted assessing: (1) non-linearity, (2) goodness-of-fit
and outlying/influential observations,27 (3) subject-specific time
effects, (4) heterogeneity of fetal striatal transplantation effect
among subjects, (5) confounding adjustment and use of propen-
sity score, (6) SEs estimates by bootstrap/jackknife. PET imaging
differences between pretransplantation and follow-up normal-
ised values were assessed by the paired t test adjusting for multi-
plicity. SPECT imaging differences between pretransplantation
and follow-up times normalised values were assessed by linear
mixed models. The potential effect of the length of follow-up
on the SPECT difference from baseline was assessed comparing
different models by AIC/BIC.22
RESULTS
Patients were followed-up from disease onset for 309.3 person-
years (median 11.2 years, maximum 21.6). No significant differ-
ences in demographic and disease-related baseline characteristics
emerged between transplanted and not-transplanted patients
(tables 1,2 and 4). In particular, homogeneity tests showed: sex
p=0.22 (Fisher’s Exact test); onset age p=0.12 (Student t test);
calendar year of onset p=0.08 (Student t test); years of educa-
tion p=0.48 (Student t test); CAG repeats p=0.12 (Student t
test); affected parent p=0.28 (Fisher’s Exact test); symptom at
onset p=0.84 (Fisher’s Exact test); DB p=0.51 (Student t test);
UHDRS functional p=0.36, behavioural p=0.78, cognitive
p=0.50, motor p=0.10 (Student t test).
Grafted patients
Follow-up ranged from 6.8 to 21.6 years (median, 13.0 years)
since disease onset. Median post-transplantation follow-up was
4.3 years, minimum 2.8, maximum 5.1 years. In Patient 2, sub-
dural haematomas were surgically evacuated 1 month after each
stereotaxy, without neurological consequences. After grafting,
no adjunctive symptomatic drugs were introduced to any
patient. Patient 1 experienced weight loss, fever, worsening of
the chorea and leukopenia related to a left thigh abscess
21 months after transplantation.14 Patients 2 and 7 died of
sudden death, respectively, at 16.2 and 10.1 years since disease
onset (4.1 years and 3.1 years after grafting), without
graft-related events. Patient 3 died of pneumonia at 16.4 years
since onset (4.2 years after transplantation). We were not able to
perform pathological study on the brain of deceased patients.
Follow-up times and frequency of morphological and meta-
bolic neuroimaging studies are reported in online-only material
table S1B. Preoperative MRI showed striatal/cortical atrophy.
The last available MRI (median 4.3 years, maximum 5.1 years),
revealed no graft development in one patient, and 3 mm
maximum diameter tissue nodules exhibiting moderately hyper-
intense signal in T2-weighted images in the neostriatum in
Table 3 Details of the transplantation procedure in 10
Huntington’s disease patients
ID Side of grafting Number of tracks
Total number of
grafted cells (×106)
1 Right 4 5.60
Left 5 5.85
2 Right 5 3.63
Left 3 2.85
3 Left 4 4.10
Right 5 4.85
4 Right 5 5.13
Left 6 6.30
5 Left 7 4.60
Right 9 7.20
6 Right 8 7.35
Left 8 11.70
7 Right 8 20.00
Left 8 8.80
8 Right 9 9.00
Left 8 5.44
9 Right 7 9.45
Left 8 4.56
10 Right 8 5.20
Left 7 6.65
At the level of each stereotactic track, a total of 50 μL of grafting suspension was
injected.
The table has two lines for each patient. The not-dominant side operated firstly is
reported in the first line.
ID, patient identifier.
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five patients. Large tissue nodules, exhibiting moderately
inhomogeneous hyperintense T2 signal, in the neostriatum
(figure 1A), frontal lobe and, in one case also in the ventral stri-
atum, were seen mono/bilaterally in four patients.14 Such large
tissue nodules remained unchanged at last follow-up.
Pretransplantation PET studies demonstrated severe striatal
hypometabolism in all grafted patients, more pronounced in the
caudate than in the putamen, associated with moderate cortical
hypometabolism (figure 1A). Two years after grafting, [18F]FDG
PET showed significant striatal metabolic increase and slight
bilateral increment of cortical metabolism, which remained
stable up to 4 years (figure 1B). [123I]IBZM SPECT was per-
formed only in patients who tolerated drug washout. Significant
striatal D2-receptor binding increase was found (figure 1C). The
increase was reached at 12 months and remained stable (best
fitting model using AIC/BIC). All patients complied with
immunosuppression. Donor-specific anti-HLA antibodies
appeared 1.2–3.6 years after the first surgery in five patients,
whose immunosuppression regimen with cyclosporine A is con-
tinuing up to now.
Not-transplanted patients
Follow-up ranged from 5.3 to 20.6 years (median, 10.2 years)
since disease onset. Patient 26 experienced sudden death
19.0 years after disease onset; patients 14 and 17 died of pneu-
monia 18.6 and 14.0 years, respectively, since disease onset. Six
patients have experienced one or more psychotic episodes since
enrolment in the study. The incidence of psychotic events was
higher in not-transplanted than in transplanted patients (6/16 vs
0/10; Fisher’s Exact test p=0.053).
UHDRS results
Scores have been routinely available since 2004, at a median
time of 5.7 years since disease onset, for 113.2 follow-up
person-years. On the whole, 202 tests were administered.
Transplanted and not-transplanted patients were evaluated 11–
21 and 3–6 times, respectively (see also online-only material
table S1A). Linear mixed models, taking into account the longi-
tudinal features of the data with repeated measurements per
subject, adjusting for the effect of baseline disease burden on
the rate of progression of the disease to control for regression
to mean effect, were fitted (table 5, figure 2, online-only mater-
ial tables S2A–C). Fetal striatal transplantation effect is
expressed by comparing the slope (disease progression over
time) before and after transplantation (change-in-slope Δslope)
and, as secondary outcome, measuring the immediate change at
transplantation (change-in-intercept Δintercept). Remember that
the slope is the change in each outcome per 1-year increase
since disease onset, and represents the disease progression over
time. The sign of the coefficient depends on the outcome
actually measured, with higher total motor scores and total
behavioural scores being worse, and lower total cognitive scores
and total functional scores being worse. The change-in-slope is
the difference between the slope before and after transplant-
ation. Table 5, left panel, reports regressions on the whole set of
enrolled patients’ measurements; in table 5, right panel, regres-
sions are restricted only to measurements of patients who
underwent transplantation (online-only material tables S2A–C).
The analysis strategy assumes that the disease history of not-
transplanted patients did not differ from the disease history of
transplanted patients if not transplanted: indeed, we tested an
interaction term on all fitted models, and this resulted not statis-
tically significant. However, by comparing the left and right
panels, we can judge the stability of the results. We found an
adjusted decrease in motor performance of 5.2 units/year (95%
CI 3.9 to 6.5) in the whole patients’ series and of 6.7 units/year
(95% CI 5.1 to 8.3) among grafted patients only.
Transplantation had an immediate positive effect, that is, with
an estimated change-in-intercept of −2.3 units (95% CI −5.8 to
1.2) in the whole patients’ series and −6.8 units (95% CI −10.6
to −3.0) among grafted patients (table 5). Transplantation also
had a long-lasting positive effect over a 4-year postoperative
period, slowing the rate (change-in-slope) by −0.9 units/year
(95% CI −1.6 to −0.2) in the whole series, and −2.0 units/year
(95% CI −2.8 to 1.2) among grafted patients. The rate of
deterioration of total motor scores was contrasted by transplant-
ation, with an immediate improvement in performance shortly
after grafting and a reduction of the rate of change (figure 3).
The transplantation effect was present, but with wider CI, for
total cognitive scores, and scarcely evident for total behavioural
and functional scores. Figure 2A reports regression analysis
results for each item of motor UHDRS (see online-only material
table S2B). Chorea and ocular movements mostly benefited
from transplantation. Figure 2B (see online-only material
table S2C) reports results for each item of cognitive UHDRS.
All cognitive items were positively affected by transplantation in
the grafted patients’ series. Using the total HD patients’ series,
only symbol digit combination was improved. Alternative
models were explored in the sensitivity analysis (see online-only
material), but our results appeared robust and no major differ-
ences were found under alternative modelling.
To appreciate the clinical relevance of our findings, we calcu-
lated the impact of fetal striatal transplantation in terms of time
gained in less severe condition. The transplantation effect was
to reduce the rate of progression from 5.2 to 5.2−0.9=4.3
scores per year. In other words, to worse by 30 units the total
motor score, transplanted patients need 7.0 years instead of 5.8,
about 1 year and half gained in better health. Table 6 reports
these calculations using the average deterioration observed
among not-transplanted patients for each main UHDRS, that is,
Table 4 Mean and median of baseline characteristics of Huntington’s disease patients at study entry
UHDRS total scores
Onset age in years Years of education CAG DB Functional Behavioural Cognitive Motor
Grafted patients
Mean 37.8 9.8 48.1 442.2 8.3 19.4 101.1 35.6
Median 39.0 8.0 47.5 433.5 9.5 19.0 111.5 36.0
Not-grafted patients
Mean 43.9 8.7 45.2 406.6 6.7 17.8 86.4 49.1
Median 42.0 8.0 46.0 391.0 6.0 15.5 79.5 52.0
CAG, cytosine-adenine-guanine; DB, disease burden measured as (CAG number–35.5)×age-at-onset23; UHDRS, Unified Huntington’s Disease Rating Scale.
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the estimated deterioration time, and the estimated transplant-
ation impact in terms of time the patient has spent in a less
invalidating condition.
DISCUSSION
Neurotransplantation has been explored since the 1990s as a
possible therapy for HD.1 Ethical issues have been raised when
fetal tissues are collected as a graft source.29 Indeed,
neurotransplantation remains highly experimental, and clinical
trials are lacking. Previous fetal striatal transplantation studies
have been carried out in a few patients.1 Kopyov et al3 reported
three transplanted subjects showing slight improvement of
motor and cognitive functions at 12-month follow-up. Hauser
et al5 described no significant changes in motor and functional
scores at 12 months in seven patients. Transplantation provided
a period of motor and cognitive improvement in three patients
Figure 1 Neuroimaging results in 10 Huntington’s disease patients who underwent human fetal striatal transplantation. (A) Co-registered MRI and
[18F]fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) of a representative case (Patient 4). Baseline [18F]FDG PET shows severe
striatal hypometabolism (arrows), with moderate cortical hypometabolism. Two-year [18F]FDG PET demonstrates metabolic stability of right striatum
(black arrow) and in the cortex, and metabolic increment in left striatum (white arrow), associated with graft growth in the same region. At 4 years
after grafting, [18F]FDG PET shows a slight reduction of right striatal (black arrow) and cortical metabolism, and stability of left striatal metabolism
(white arrow), compared to baseline and 2-year follow-up. (B) Metabolic activity in striatal and cortical regions measured by [18F]FDG PET: follow-up
vs baseline means and SDs, Bonferroni p values. At 2 years after transplantation (10 patients) right striatum: 0.72±0.12 vs 0.64±0.09, *p=0.018;
left striatum: 0.74±0.17 vs 0.56±0.14, *p=0.010; cortex 0.99±0.14 vs 0.94±0.13, *p=0.058. At 4 years after grafting (7 patients) right striatum:
0.71±0.08, *p=0.026; left striatum: 0.72±0.17, *p=0.034; cortex 0.98±0.15, p=0.220. (C) Preoperative and postoperative striatal D2-receptor
binding measured by [123I]iodobenzamide ([123I]IBZM) single photon emission CT (SPECT) in five patients (ID 2, 3, 4, 7, 8) at baseline, three patients
(ID 3, 4, 7) at 12 months, one patient (ID 8) at 18 months, one patient (ID 2) at 24 months after transplantation. Patient identifier (ID) as in Table
1. Postoperative versus preoperative SPECT showed a significant increase in striatal D2-receptor binding. R: right (*p=0.024) and L: left (*p<0.001).
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of Bachoud-Lévi et al9 series at 6 years, and in one patient of
Reuter et al10 series over 5 years. Recently, Barker et al8
reported no significant clinical benefit of cell transplantation in
neurological, neuropsychological and imaging assessment of five
patients followed up to 10 years. Overall, an effect of trans-
plantation remained questionable.
Our study provides evidence that transplantation is associated
with slower motor and cognitive deterioration in HD. However,
our findings should be interpreted with caution. The main
drawback of non-randomised studies is the potential unbalance
between treatment and control condition. In our study, the com-
parison is the disease progression rate before and after trans-
plantation, which is a within-subject comparison. The
not-transplanted patients’ series and the pretransplantation
period of observation in the transplanted cases provided an esti-
mate of disease progression over time in the absence of trans-
plant. The potential bias is related to lack of homogeneity of
disease progression in not-transplanted patients and grafted
patients before transplantation. We did not find major differ-
ences in that, but we preferred to present two analyses, the first
using the total patients’ series and the second using only grafted
patients. A strong placebo effect has been demonstrated in the
context of Parkinson’s disease.30 The difference between the
transplantation effect estimated on the grafted patients’ series
and the transplantation effect estimated on the total HD
patients’ series (see table 5, figure 2 and online-only material
tables S2A–C) may be interpreted due to a placebo effect and/or
a residual regression to the mean effect. In fact, we found a
slightly higher pretransplantation deterioration rate in patients
actually transplanted. Notwithstanding these potential biases,
our report is important because randomised trials have not been
approved for fetal striatal transplantation yet.21
Follow-up measurements varied in number and timing among
patients, depending on the patient-specific clinical course. We have
taken into account these data features by linear mixed models.
Patients entered the transplantation protocol at different times
since onset and, therefore, we cannot disentangle a potential calen-
dar period effect from the effect of time since disease onset. This
did not introduce important biases because in the last 15 years
no decisive therapeutics has been introduced.31 We adjusted for
disease burden at onset and other confounding variables. Our
results were robust as documented in the sensitivity analysis (see
online supplementary data), when we also accounted for hetero-
geneity of transplantation effect among patients. Our post-
transplantation follow-up was around 4 years, and extrapolation
to longer follow-up times should be considered with attention.
In our study, fetal striatal grafting was associated with slower
motor and cognitive deterioration rate, but did not halt disease
Table 5 Human fetal striatal transplantation effect on Unified Huntington’s Disease (HD) Rating Scale (UHDRS) total scores
Total HD patients’ series Grafted HD patients’ series
Slope (95% CI) Δintercept (95% CI) Δslope (95% CI) Slope (95% CI) Δintercept (95% CI) Δslope (95% CI)
Functional −0.7 (−1.0 to −0.4) −1.0 (−1.9 to −0.1) 0.1 (−0.1 to 0.2) −0.9 (−1.2 to −0.5) −0.6 (−1.6 to 0.3) 0.2 (0.0 to 0.4)
Behavioural −1.1 (−2.2 to 0.01) −1.0 (−4.5 to 2.6) 0.2 (−0.5 to 0.9) 0.3 (−1.2 to 1.8) −3.3 (−7.0 to 0.4) −0.5 (−1.3 to 0.2)
Cognitive −11.5 (−16 to −7.3) −2.0 (−14.4 to 10.3) 2.7 (0.1 to 5.3) −15.0 (−20.0 to −9.5) 7.4 (−5.2 to 20.1) 4.1 (1.8 to 6.5)
Motor 5.2 (3.9 to 6.5) −2.3 (−5.8 to 1.2) −0.9 (−1.6 to −0.2) 6.7 (5.1 to 8.3) −6.8 (−10.6 to −3.0) −2.0 (−2.8 to −1.2)
Left panel: total HD patients’ series, right panel: grafted patients only.
UHDRS functional and cognitive score decrease indicates deterioration (better up), behavioural and motor score increase indicates deterioration (better down).
Columns 1 and 4: variation (‘slope’, in units/year) of total scores of the UHDRS over time since onset of symptoms.
Change-in-intercept (columns 2 and 5) and change-in-slope (columns 3 and 6): transplantation effect measures. Bold values if false discovery rate <0.10. Δintercept: average difference in
total scores at time of transplantation. Δslope: difference in slope before/after transplantation.
Figure 2 Human fetal striatal transplantation effect on the motor and cognitive items of the Unified Huntington’s Disease Rating Scale scores.
Funnel plot of effect estimates (Δslope: difference in slope before/after transplantation) for motor (A) and cognitive (B) items with thresholding lines
(dot: Bonferroni p value; solid: false discovery rate <0.05; dashed: false discovery rate <0.10). A point labels: 1 chorea, 2 dystonia, 3 gait, 4 ocular
pursuit, 5 saccade initiation, 6 saccade velocity, 7 dysarthria, 8 tongue protrusion, 9 finger taps, 10 pronate/supinate hands, 11 Luria, 12 rigidity,
13 bradykinesia, 14 tandem walk, 15 retropulsion, 16 dystonia axial, 17 dystonia articular, 18 chorea axial, 19 chorea limbs. B point labels:
1 phonemic verbal fluency, 2 Stroop reading fluency, 3 Stroop colour naming, 4 Stroop interference, 5 symbol digit combination.
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progression. Bachoud-Levy et al9 focused on an immediate
relief or even improvement that plateaued over about 2 years,
followed by a progression of symptoms. Barker et al8 reported
no sustained functional benefit and concluded that this may
relate to the small amount of grafted tissue. However, no differ-
ences in the total amount of grafted cells between Barker et al8
and our study are apparent (table 3), suggesting that other
patient/donors features need further exploration. Barker et al8
analysed the individual evolution of each outcome on ‘time
since transplantation’ matching grafted patients with a compar-
able series of not-transplanted patients defining a counterfactual,
hypothetical time of transplantation for them. We found that
grafted patients after transplantation exhibited a slower disease
progression, but after some years, the patients’ condition will be
the same as before transplantation. This does not imply absence
of effect, because the correct comparison is between the
observed and the expected condition if transplantation had not
taken place (table 6). To do this, it is important to adjust for
time since disease onset and burden of disease at onset. The
Bachoud-Lévi et al9 analysis could be considered similar to what
we addressed in measuring the change-in-intercept after trans-
plantation. This variation occurring immediately after surgery
should be discussed as a potential tractotomy effect.
Chorea was the most responsive sign in limbs and trunk.
Dystonia benefited in a minor way, while fetal striatal transplant-
ation did not affect bradykinesia and rigidity. Effects were also
seen in the cephalic district, particularly tongue protrusion and
eye movements. Long-term stabilisation of eye movements has
already been reported.9 Since neural circuits involved in ocular
movements are mainly in the caudate body and tail, regions
outside the tissue deposits, this benefit cannot be explained by a
direct mechanism of substitution of striatal neurons. We did not
observe any significant improvement in gait or postural control.
Inadequate grafting of postcommissural putamen has been
hypothesised as a possible cause.9 In our study, even extensive
grafting of postcommissural putamen7 did not result in signifi-
cant improvement in gait and postural competence. We specu-
late that the circuits involved are no longer adequately
represented in the residual putamen and, therefore, unlikely to
be restored by a substitutive mechanism.
Post-transplantation decline in cognitive tasks of UHDRS was
slower than in controls. Partial recovery of learning motor abil-
ities was suggested by improvement in Luria item. These results
may relate to a better allocation of attention resources and
suggest a beneficial effect of fetal striatal grafting on the execu-
tive domain. A modulation of the excitatory cortical efferences
probably explains these cognitive benefits. The relative impact
of graft development and/or of thalamocortical tractotomy on
this effect is not known. Even if grafted patients showed
improvement in judgment capacity and awareness, their behav-
iour was not significantly affected by transplantation.
Tractotomy per se might explain the early feeling of well-being
reported by patients just after the first surgery, which was per-
formed on the non-dominant hemisphere.
Benefits to functional capacity have been reported.9 Grafted
patients in our study did not show substantial functional improve-
ment. Six patients recovered their previous capacities or simple
home activities, but the benefit persisted in only three of them.
Transplantation induced persistent improvement in striatal
metabolic activity, suggesting graft survival and development. The
effects seen at the 2-year PET reversed the progressive annual
Table 6 Clinical impact of human fetal striatal transplantation in Huntington’s disease
Not-grafted HD patients’ series Total HD patients’ series
Grafted HD patients’
series
Worsening in UHDRS total
scores*
Years to worse in absence of
grafting†
Years to worse
in presence of
grafting‡
Savings
(years)§ Savings (years)§
Functional −5 7.1 (5.0 to 12.5) 7.6 (5.2 to 14.7) 0.5 (−2.6 to 4.2) 1.6 (−1.1 to 5.9)
Behavioural Not calculable
Cognitive −40 3.5 (2.5 to 5.5) 4.5 (2.9 to 10.2) 1.0 (0.1 to 12.0) 1.0 (0.2 to 3.6)
Motor 30 5.8 (4.7 to 7.5) 7.0 (5.3 to 10.0) 1.2 (0.02 to 2.8) 2.6 (1.3 to 4.9)
*Difference between average values at study entry and average values at the end of the study for not-grafted Huntington’s Disease (HD) patients (clinically significant worsening: W).
†Number of years needed to reach such difference in not-transplanted HD patients (number of years needed to worse: NNWnt). From the regression analysis results as: NNWnt=W/
slope.
‡Number of years needed to reach such difference in presence of grafting (number of years needed to worse: NNWt). From the regression analysis results as: NNWt=W/(slope
+change-in-slope).
§Difference NNWt—NNWnt. NNW and savings in years (95% bootstrap CIs).28
UHDRS, Unified Huntington’s Disease Rating Scale.
Figure 3 Unified Huntington’s Disease Rating Scale total motor
scores deterioration in Huntington’s disease patients. Scatter plot of
202 measurements on 26 patients and fitted patient-specific pre and
post- transplantation regression lines of 10 grafted patients. Total
motor scores (y-axis, better down) over time since onset of symptoms
(x-axis, in years).
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decrease of striatal metabolism expected in HD.32 Thereafter, as
already reported by Gaura et al33 and by Bachoud-Lévi et al,9 the
slight decline in striatal metabolism supports the hypothesis that
the pathological process does not stop. Cortical metabolism did
not decrease after grafting, contrary to progressive annual decrease
expected in HD.34 An increase in D2-receptor binding as mea-
sured by [123I]IBZM SPECT suggests progression in striatal differ-
entiation of the graft as already assessed using 11C-raclopride
PET.10 Overall, these data suggest that striatal/cortical hypometa-
bolism is reversible in HD, and striatal grafts can anatomically and
functionally replace degenerated neurons, thus supporting the
rationale of transplantation.
In conclusion, human fetal striatal transplantation favourably
affected the motor and cognitive course of HD. Longer
follow-up is necessary to understand whether transplantation
can have a significant impact on the natural history of the
disease in terms of overall survival and/or time spent in earlier
disease stages. If further studies will confirm our results, it
might be worthwhile to perform transplantation in less severely
affected patients.
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